Therapeutic Advances in Ophthalmology最新文献

筛选
英文 中文
Evaluation of extended depth-of-focus hydrophobic intraocular lens with an optic concept based on combination of high-order aberrations. 基于高阶像差组合的光学概念评估扩大焦深疏水性人工晶状体。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-10-03 eCollection Date: 2023-01-01 DOI: 10.1177/25158414231200108
Pavel Stodulka, Zuzana Pracharova
{"title":"Evaluation of extended depth-of-focus hydrophobic intraocular lens with an optic concept based on combination of high-order aberrations.","authors":"Pavel Stodulka,&nbsp;Zuzana Pracharova","doi":"10.1177/25158414231200108","DOIUrl":"10.1177/25158414231200108","url":null,"abstract":"<p><strong>Background: </strong>Extended depth-of-focus (EDOF) intraocular lenses (IOLs) provide a continuous range of uncorrected vision at different distances.</p><p><strong>Objective: </strong>To assess visual acuity, refractive outcomes, and patient satisfaction after cataract surgery using the LuxSmart EDOF IOL (Bausch+Lomb).</p><p><strong>Design: </strong>A two-center, prospective observational clinical study.</p><p><strong>Methods: </strong>This study includes patients who have undergone bilateral phacoemulsification with bilateral implantation of the LuxSmart EDOF IOL, with the aim of achieving emmetropia. Visual acuity (VA) and subjective refraction were obtained in all patients preoperatively and at 1 week, 1 month, 3 months, and 6 months postoperatively. Subjective measures were obtained using the Catquest-9SF questionnaire and the Patient-Reported Spectacle Independence Questionnaire (PRSIQ). Contrast sensitivity and a glare assessment were undertaken postoperatively. Safety outcomes were additionally assessed.</p><p><strong>Results: </strong>Sixty eyes from thirty patients were recruited for this study. The mean spherical equivalent was 1.04 ± 1.67 D preoperatively and -0.30 ± 0.46 D at 6 months. Monocular uncorrected distance VA was 0.57 ± 0.32 (logMAR) preoperatively and 0.09 ± 0.12 (logMAR) at 6 months. Mean 6-month monocular uncorrected VA was 0.11 ± 0.13, 0.12 ± 0.15, and 0.31 ± 0.15 (logMAR) at 80, 66, and 40 cm, respectively. More than 90% of patients were either fairly or very satisfied with their vision. There was one case of suspected vitreomacular traction postoperatively.</p><p><strong>Conclusion: </strong>The LuxSmart EDOF IOL offers good refractive, VA, and safety outcomes. The single elongated focal point designed to enhance the DOF shows good results for VA and patient satisfaction.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/e2/10.1177_25158414231200108.PMC10548805.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41129912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular manifestations of COVID-19 in pediatric patients. COVID-19在儿童患者中的眼部表现。
IF 2.3
Therapeutic Advances in Ophthalmology Pub Date : 2023-03-14 eCollection Date: 2023-01-01 DOI: 10.1177/25158414221149916
Parul Ichhpujani, Rohan Bir Singh, Hennaav Kaur Dhillon, Suresh Kumar
{"title":"Ocular manifestations of COVID-19 in pediatric patients.","authors":"Parul Ichhpujani, Rohan Bir Singh, Hennaav Kaur Dhillon, Suresh Kumar","doi":"10.1177/25158414221149916","DOIUrl":"10.1177/25158414221149916","url":null,"abstract":"<p><p>The coronavirus disease-19 (COVID-19) infection may remain asymptomatic or may have several different presentations. Although this disease primarily affects the respiratory system, systemic manifestations affecting the gastrointestinal, cardiovascular, neurological, otorhinolaryngologic, and ophthalmic systems have been reported. Ophthalmic signs may be the first and only sign of COVID-19 infection in children. In the current narrative review, we report the ophthalmic manifestations of COVID-19 in the pediatric age cohort. We performed a comprehensive literature search for the publications on ophthalmic manifestations of COVID-19 in children between 1 March 2020 and 1 January 2022 and compiled the ophthalmic manifestations of this entity among the pediatric population. Conjunctivitis is the most common ophthalmic manifestation in children and can develop at any stage of the disease. Ophthalmic manifestations are seen more commonly in children with severe systemic disease. Long-term and indirect consequence of the COVID-19 disease is the rise of myopia among children. Ophthalmic signs may be the first and only sign of COVID-19 infection in children. Pediatricians, as well as ophthalmologists, must keep observing all children with COVID-19 closely for ophthalmic signs.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a6/a0/10.1177_25158414221149916.PMC10015281.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9146780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights into amiodarone induced retinal and optic nerve toxicity: functional and structural changes. 胺碘酮诱导视网膜和视神经毒性的新见解:功能和结构变化。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414231194159
Weam Mohamed Ebeid, Amany Abd El-Fattah El-Shazly, Norhan Mohamed Kamal, Emad Effat Fakhary, Amr Mansour, Doaa Maamoun Ashour
{"title":"New insights into amiodarone induced retinal and optic nerve toxicity: functional and structural changes.","authors":"Weam Mohamed Ebeid,&nbsp;Amany Abd El-Fattah El-Shazly,&nbsp;Norhan Mohamed Kamal,&nbsp;Emad Effat Fakhary,&nbsp;Amr Mansour,&nbsp;Doaa Maamoun Ashour","doi":"10.1177/25158414231194159","DOIUrl":"https://doi.org/10.1177/25158414231194159","url":null,"abstract":"<p><strong>Background: </strong>Amiodarone is widely used for heart arrhytmia. Previous studies have suggested the possibility of optic neuropathy with the chronic use of this drug.</p><p><strong>Objectives: </strong>To identify structural or functional changes in the retina and optic nerve in patients on chronic amiodarone therapy without visual complaints.</p><p><strong>Methods: </strong>This observational study included 15 eyes of 15 patients with cardiac arrythmia on chronic amiodarone treatment and 15 healthy matched subjects as a control group. All subjects underwent electrophysiological tests [pattern visual evoked potential (PVEP), pattern electroretinogram (PERG), multifocal electroretinogram (mfERG), and optical coherence tomography (OCT) and angiography (OCTA)].</p><p><strong>Results: </strong>There were no statistically significant differences between the two groups regarding the PVEP, PERG, and the mfERG parameters. Macular and optic nerve head OCT and OCTA have not shown statistically significant differences except for the morphological parameters of the optic disc (<i>p</i> = 0.008 for the horizontal and <i>p</i> = 0.013 for vertical cup/disc ratio and <i>p</i> = 0.045 for rim area).</p><p><strong>Conclusion: </strong>Patients on chronic amiodarone therapy have not shown evident structural or functional changes in the retinal or optic nerve as demonstrated by electrophysiological tests, OCT, and OCTA results compared to controls.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/9f/10.1177_25158414231194159.PMC10493063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10285127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scheimpflug imaging for evaluation of intraocular lens position in modified flanged scleral fixated intraocular lens. 改良法兰巩膜固定人工晶状体中人工晶状体位置的评价。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414221147208
Avadhesh Oli, Anil Yadav, J Ganesh Babu, Divya Balakrishnan
{"title":"Scheimpflug imaging for evaluation of intraocular lens position in modified flanged scleral fixated intraocular lens.","authors":"Avadhesh Oli,&nbsp;Anil Yadav,&nbsp;J Ganesh Babu,&nbsp;Divya Balakrishnan","doi":"10.1177/25158414221147208","DOIUrl":"https://doi.org/10.1177/25158414221147208","url":null,"abstract":"<p><strong>Background: </strong>Scleral fixation of intraocular lens (IOLs) is the most preferred technique for the management of aphakia and the techniques have evolved over the years. These methods have their advantages and disadvantages, however, the major concern being the position of the intraocular lens, its stability and complications. The final IOL position is the major determinant of the final visual acuity, and various imaging modalities have been used to quantify the IOL tilt.</p><p><strong>Objectives: </strong>Use of Scheimpflug imaging to evaluate the IOL tilt in modified flanged scleral-fixated intraocular lens (MFSIOL).</p><p><strong>Design: </strong>Retrospective chart review of 41 consecutive patients who underwent MFIOL.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of 41 consecutive patients who underwent MFIOL. The baseline and final best-corrected visual acuity (BCVA), refractive error, and clinical examination findings were recorded. The vertical and horizontal tilts of the IOLs were calculated using the Scheimpflug image. The IOL tilt (in degrees) in the vertical and horizontal axes was the primary outcome and the BCVA, residual refractive error, intraocular pressure, and surgical complications were secondary outcome measures.</p><p><strong>Results: </strong>The mean baseline BCVA was logMAR 0.49, which improved to logMAR 0.356 (<i>p</i> < .005) after the surgery. The mean IOL tilt in the vertical axis was 3.40° (range of 0.0°-8.5°, interquartile range: 1.21-5.66) and in the horizontal axis was 1.35° (range of 0.60°-4.620°, interquartile range: 0.44-1.86), respectively. There was no correlation between angle of IOL tilt and UCVA (<i>r</i> = 0.089, <i>p</i> = 0.580), BCVA (<i>r</i> = 0.109, <i>p</i> = 0.498), final spherical error (<i>r</i> = 0.081, <i>p</i> = 0.615), cylindrical error (<i>r</i> = 0.207, <i>p</i> = 0.195), axial length (<i>r</i> = 0.105, <i>p</i> = 0.514), and IOL power (<i>r</i> = -0.139, <i>p</i> = 0.388).</p><p><strong>Conclusion: </strong>Modified flanged IOL (MFIOL) is an alternative technique for intrascleral fixation of IOL resulting in good lens stability. The IOL tilt achieved by this technique is minimal and did not influence the final visual outcome or spectacle correction. Scheimpflug imaging is simple and non-invasive method to measure the IOL tilt.</p><p><strong>Plain language summary scheimpflug imaging for modified flanged scleral fixated lens position: </strong>This study on 41 eyes was aimed to analyze the lens tilt using Scheimpflug imaging in cases of modified flanged scleral fixation of intraocular lens (MFSFIOL), which is a novel technique to minimize the complications and simplify the procedure. The intraocular lens (IOL) remained stable with an acceptable range of vertical and horizontal tilt. There was no significant effect of IOL tilt on the final best-corrected visual acuity (BCVA) or spectacle correction. Scheimpflug imaging is an accurate and non-invas","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/79/10.1177_25158414221147208.PMC9841840.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10548398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world efficacy of the intrascleral ciliary sulcus suprachoroidal microtube technique in Black and Afro-Latinx patients with glaucoma: a 1-year retrospective study. 巩膜睫状沟脉络膜上微管技术治疗黑人和拉丁裔青光眼患者的实际疗效:一项为期1年的回顾性研究。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414221147445
Daniel Laroche, Gideon Nkrumah, Chester Ng
{"title":"Real-world efficacy of the intrascleral ciliary sulcus suprachoroidal microtube technique in Black and Afro-Latinx patients with glaucoma: a 1-year retrospective study.","authors":"Daniel Laroche,&nbsp;Gideon Nkrumah,&nbsp;Chester Ng","doi":"10.1177/25158414221147445","DOIUrl":"https://doi.org/10.1177/25158414221147445","url":null,"abstract":"Background: Suprachoroidal surgery can lower intraocular pressure and medication use. There is currently no commercial suprachoroidal product on the market. Here, we report our 1 year results of a novel ciliary sulcus suprachoroidal microtube technique. Purpose: To determine the real-world efficacy of intrascleral ciliary sulcus suprachoroidal microtube technique in Black and Afro-Latinx patients with glaucoma refractory to topical ocular hypertensive medications. Methods: A retrospective non-comparative single center study of 36 Black and Afro-Latinx patients with glaucoma and pseudophakia who underwent intrascleral ciliary sulcus suprachoroidal microtube surgery for glaucoma as a stand-alone procedure at a single practice. Investigated parameters were number of medications, visual acuity (VA), intraocular pressure (IOP), mean deviation on visual field (VF) test. Success was defined as (a) IOP ⩽ 15 mmHg and or ⩾ 20% reduction in IOP and (b) a reduction in number of medications. We used paired t-test to compare baseline and follow-up parameters. Results: We reviewed a total of 36 patients who had undergone the procedure. Twenty had success with 12-month follow-up in the study. The mean number of medications decreased significantly from 4.2 ± 1.0 preoperatively to 2.4 ± 1.7 in 12 months (p = 0.021) with five patients being medication free. In addition, the IOP decreased significantly from 21 ± 8.2 to 13.5 ± 4.4 mmHg (p = 0.032). In the 20 patients who had 12-month follow-up, the VA remained stable from Log Mar 0.62 ± 0.6–0.46 ± 0.6 (p = 0.052). VF in patients with successful procedure (no further interventions) remained stable from baseline mean deviation of –16.53 ± 10.04 to –16.82 ± 9.80 dB at 6–12 months. Adverse effects were transient and included IOP spike, hypotony, hyphema, and cornea edema that were treated and resolved. Conclusions: This 12-month retrospective study demonstrated that intrascleral ciliary sulcus suprachoroidal microtube surgery can reduce IOP and medication burden in pseudophakic patients with glaucoma. However, despite several successes, surveillance should take place for IOP spikes, possible tube obstruction, and need for additional glaucoma surgery.","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/3b/10.1177_25158414221147445.PMC9880568.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10584243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A medication-wide association study to identify medications associated with incident clinically significant diabetic retinopathy. 一项全药物相关性研究,以确定与临床显著性糖尿病视网膜病变相关的药物。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414221139002
Ruilin Xiong, Wei Wang, Xianwen Shang, Yixiong Yuan, Yifan Chen, Lei Zhang, Katerina V Kiburg, Zhuoting Zhu, Mingguang He
{"title":"A medication-wide association study to identify medications associated with incident clinically significant diabetic retinopathy.","authors":"Ruilin Xiong,&nbsp;Wei Wang,&nbsp;Xianwen Shang,&nbsp;Yixiong Yuan,&nbsp;Yifan Chen,&nbsp;Lei Zhang,&nbsp;Katerina V Kiburg,&nbsp;Zhuoting Zhu,&nbsp;Mingguang He","doi":"10.1177/25158414221139002","DOIUrl":"https://doi.org/10.1177/25158414221139002","url":null,"abstract":"<p><strong>Background: </strong>Diabetic retinopathy, a common microvascular complication of diabetes mellitus, is one of the leading causes of vision loss worldwide. Although some oral drugs have been suggested to affect the risk of diabetic retinopathy, systematic evaluation about the associations between medications and diabetic retinopathy is still absent.</p><p><strong>Objective: </strong>To comprehensively investigate associations of systemic medications with incident clinically significant diabetic retinopathy (CSDR).</p><p><strong>Design: </strong>Population-based cohort study.</p><p><strong>Methods: </strong>From 2006 to 2009, more than 26 000 participants residing in New South Wales were enrolled in the 45 and Up study. Diabetic participants with self-reported physician diagnosis or records of anti-diabetic medication prescriptions were finally included in the current analysis. CSDR was defined as diabetic retinopathy cases requiring retinal photocoagulation recorded in the Medicare Benefits Schedule database from 2006 to 2016. Prescriptions of systemic medication from 5 years to 30 days prior to CSDR were retrieved from the Pharmaceutical Benefits Scheme. The study participants were equally split into training and testing datasets. Logistic regression analyses were performed for the association between each of systemic medication and CSDR in the training dataset. After controlling the false discovery rate (FDR), significant associations were further validated in the testing dataset.</p><p><strong>Results: </strong>The 10-year incidence of CSDR was 3.9% (<i>n</i> = 404). A total of 26 systemic medications were found to be positively associated with CSDR, among which 15 were validated by the testing dataset. Additional adjustments for pertinent comorbidities suggested that isosorbide mononitrate (ISMN) (OR: 1.87, 95%CI: 1.00-3.48), calcitriol (OR: 4.08, 95% CI: 2.02-8.24), three insulins and analogues (e.g., intermediate-acting human insulin, OR: 4.28, 95% CI: 1.69-10.8), five anti-hypertensive medications (e.g., furosemide, OR: 2.53, 95% CI: 1.77-3.61), fenofibrate (OR: 1.96, 95% CI: 1.36-2.82) and clopidogrel (OR: 1.72, 95% CI: 1.15-2.58) were independently associated with CSDR.</p><p><strong>Conclusion: </strong>This study investigated the association of a full spectrum of systemic medications with incident CSDR. ISMN, calcitriol, clopidogrel, a few subtypes of insulin, anti-hypertensive and cholesterol-lowering medications were found to be associated with incident CSDR.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/a6/10.1177_25158414221139002.PMC9969435.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10824067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis. 0.03%和0.1%他克莫司软膏治疗儿童春性角膜结膜炎的疗效和安全性比较。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414231173532
Bhawesh Chandra Saha, Rashmi Kumari, Anita Ambasta
{"title":"Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis.","authors":"Bhawesh Chandra Saha,&nbsp;Rashmi Kumari,&nbsp;Anita Ambasta","doi":"10.1177/25158414231173532","DOIUrl":"https://doi.org/10.1177/25158414231173532","url":null,"abstract":"<p><strong>Background: </strong>Topical immunosuppressants such as tacrolimus in different concentrations are a breakthrough in the management of recalcitrant vernal keratoconjunctivitis (VKC); however, there is a lacks of comparative studies to guide their use in VKC management.</p><p><strong>Objective: </strong>To compare the efficacy and safety of tacrolimus 0.03% and 0.1% eye ointment in the treatment of recalcitrant VKC.</p><p><strong>Design: </strong>A retrospective comparative single-centre observational study.</p><p><strong>Method: </strong>We reviewed records of a total of 48 recalcitrant VKC patients treated with two different strengths of tacrolimus ointment between April 2016 and March 2017. Of these, 39 fulfilled the inclusion criteria and were categorized into two groups, A and B, depending on the use of strength of tacrolimus (0.03% and 0.1%) used, respectively. Group A had 18 patients, while group B had 21 patients. Thirty-six patients, 18 from each group, were finally analysed and compared. Records of patients were explored for the subjective symptoms and objective sign score of the patient at baseline and at each time point. The main outcome measures were composite scoring and comparison of total subjective symptom scores (TSSSs) and total objective sign scores (TOSSs) within and between the groups at each follow-up. Percentage of patient with significant reduction in symptom and sign scores as compared with baseline was considered success of treatment. Chi-square and <i>t</i>-tests were used for comparison of outcomes between both groups.</p><p><strong>Results: </strong>Mixed variety was most commonly encountered type of VKC. The signs and symptoms were significantly reduced in patients with treatment in both groups (<i>p</i> = 0.001) in all types of VKC. However, in group B, there was significant improvement in the size of papillae (<i>p</i> = 0.04) as compared baseline in contrast to group A. Side effects like burning and stinging in group B were significantly higher as compared with group A.</p><p><strong>Conclusions: </strong>Both strengths of tacrolimus (0.03% and 0.1%) are effective in all forms of recalcitrant VKC. Papillary component of VKC responds better with higher strength (0.1%) but is associated with more significant side effects. Different strengths of tacrolimus can be used strategically depending upon the severity and clinical type of VKC to intensify outcome and minimize side effects.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/31/10.1177_25158414231173532.PMC10226287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9556811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluating the safety and efficacy of epi-off corneal cross-linking in patients with thin corneas due to keratectasia. 评价肾上腺素-off角膜交联治疗角膜扩张性薄角膜患者的安全性和有效性。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414231197064
Abigail Nieuwsma, Brandon L Vander Zee, John P Berdahl, Mitch Ibach, Tanner J Ferguson, Daniel Terveen
{"title":"Evaluating the safety and efficacy of epi-off corneal cross-linking in patients with thin corneas due to keratectasia.","authors":"Abigail Nieuwsma,&nbsp;Brandon L Vander Zee,&nbsp;John P Berdahl,&nbsp;Mitch Ibach,&nbsp;Tanner J Ferguson,&nbsp;Daniel Terveen","doi":"10.1177/25158414231197064","DOIUrl":"https://doi.org/10.1177/25158414231197064","url":null,"abstract":"<p><strong>Background: </strong>Corneal cross-linking (CXL) is a safe and effective procedure for slowing keratectasia progression in eyes with a corneal thickness of at least 400 µm. Limited research has evaluated the safety and efficacy of epi-off CXL in corneas thinner than 400 µm.</p><p><strong>Objective: </strong>To evaluate the safety and efficacy of CXL to slow keratectasia progression in eyes with <400 µm preoperative corneal thickness.</p><p><strong>Design: </strong>Retrospective chart review.</p><p><strong>Methods: </strong>This retrospective chart review included 37 eyes who underwent epi-off, iso-osmolar riboflavin corneal CXL with a preoperative thinnest point of the cornea <400 µm and had at least 6-12 months of follow-up. Preoperative and postoperative uncorrected visual acuity, best-corrected visual acuity (BCVA), thinnest point of the cornea, flat keratometry, steep keratometry, maximum keratometry (K<sub>max</sub>), need for penetrating keratoplasty, and cases of endothelial failure were recorded. Data were collected at baseline and months 3, 6, 9, and 12 post-CXL.</p><p><strong>Results: </strong>Following cross-linking, 18 eyes (47%) had improved BCVA, 13 (35%) had an unchanged BCVA, and 6 eyes (16%) had a worse BCVA (<i>p</i> = 0.05). The mean postoperative BCVA was 20/81 (0.61 LogMAR) compared to 20/121 (0.78 LogMAR) preoperatively (<i>p</i> = 0.06). K<sub>max</sub> decreased an average of 1.1 D at 3-month (<i>p</i> = 0.53) and 3.4 D at the furthest follow-up (<i>p</i> = 0.10). At the farthest follow-up, 22.7% of eyes had >1 D of K<sub>max</sub> steepening. No patients required keratoplasty and there were no cases of endothelial failure in the follow-up period.</p><p><strong>Conclusion: </strong>This research supports the safety and efficacy of epi-off, iso-osmolar CXL in eyes with <400 μm baseline corneal thickness with no patients requiring penetrating or endothelial keratoplasty, a trend toward improvement in BCVA, and K<sub>max</sub> flattening. In the future, prospective studies would be helpful to confirm these findings.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/49/b5/10.1177_25158414231197064.PMC10504847.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of obesity on ocular hemodynamics and choroidal thickness. 肥胖对眼血流动力学和脉络膜厚度的影响。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414231180985
Melek Tufek, Pinar Nalcacioglu, Mustafa Capraz, Kenan Varol, Ahmet Turan Kaya, Nihat Aydın, Caner Kara
{"title":"The impact of obesity on ocular hemodynamics and choroidal thickness.","authors":"Melek Tufek,&nbsp;Pinar Nalcacioglu,&nbsp;Mustafa Capraz,&nbsp;Kenan Varol,&nbsp;Ahmet Turan Kaya,&nbsp;Nihat Aydın,&nbsp;Caner Kara","doi":"10.1177/25158414231180985","DOIUrl":"https://doi.org/10.1177/25158414231180985","url":null,"abstract":"<p><strong>Background: </strong>Obesity affects microvascular structures. The effect of obesity on the ocular vascular system can be evaluated by changes in the choroidal thickness (CT) and retrobulbar blood flow (RBF).</p><p><strong>Objectives: </strong>To evaluate the CT and RBF parameters in obese patients with various body mass index (BMI) values and compare these parameters with normal weight, healthy subjects.</p><p><strong>Design: </strong>A prospective study.</p><p><strong>Methods: </strong>The study included 102 eyes of 102 female patients. Patients were divided into three groups according to BMI as group 1 with a BMI of 18.5-24.99 (<i>n</i> = 32), normal weight group; group 2 with a BMI of 30-34.99 (<i>n</i> = 35), as obese class I; and group 3 with a BMI of 35-39.99 (<i>n</i> = 35), as obese class II. The peak systolic velocity (PSV), end-diastolic velocity (EDV), resistive index, and pulsatility index values of the central retinal artery (CRA) and ophthalmic artery (OA) were evaluated with color Doppler ultrasonography. CT was measured at the subfoveal area and at 500-µm intervals nasal and temporal to the fovea up to a distance of 1500 µm by using the enhanced depth imaging technique of optical coherence tomography. Intraocular pressure (IOP) was measured with a Goldmann applanation tonometry.</p><p><strong>Results: </strong>There was a significant difference in IOP values within the groups with the highest values in group 3 (17.6 ± 2.1 mmHg) and the lowest in group 1 (12.4 ± 1.7 mmHg). The CT in groups 2 and 3 was found to be statistically significantly lower than that in group 1 at all measurement points (<i>p</i> < 0.001). There was a statistically significant negative correlation between CT at all measurement points and BMI (<i>p</i> < 0.001). The mean CRA PSV, EDV, and OA EDV values were statistically significantly lower in each obese group than those values in group 1 (<i>p</i> < 0.001). The OA PSV values were significantly lower in group 3 (36.5 ± 5.9 cm/s) than those in group 2 (43.8 ± 4 cm/s) and group 1 (44.6 ± 5.2 cm/s) (<i>p</i> < 0.001). Also, significant associations were found between BMI and CRA PSV, CRA EDV, and OA PSV values (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Obesity may predispose to eye pathologies by changing the ocular vascular circulation.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/4d/10.1177_25158414231180985.PMC10333989.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10193732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A cross-sectional study investigating the effects of argon laser retinal photocoagulation on lens clarity and corneal endothelial cells. 横断面研究氩激光视网膜光凝对晶状体清晰度和角膜内皮细胞的影响。
IF 2.5
Therapeutic Advances in Ophthalmology Pub Date : 2023-01-01 DOI: 10.1177/25158414231189071
Uğur Yılmaz, Hüseyin Kaya, Selen Akbulut, Yasin Durkal
{"title":"A cross-sectional study investigating the effects of argon laser retinal photocoagulation on lens clarity and corneal endothelial cells.","authors":"Uğur Yılmaz,&nbsp;Hüseyin Kaya,&nbsp;Selen Akbulut,&nbsp;Yasin Durkal","doi":"10.1177/25158414231189071","DOIUrl":"https://doi.org/10.1177/25158414231189071","url":null,"abstract":"<p><strong>Background: </strong>The mechanism of argon laser retinal photocoagulation (ALRP) treatment is to apply thermal-induced retinal pigment epithelium damage. Light passes through the anterior optical segments of the eye to reach the retina. Lens densitometry is a noninvasive and quantitative measurement providing information about corneal and lens clarity.</p><p><strong>Objectives: </strong>This study aimed to investigate whether laser light affects lens clarity and corneal endothelial cells.</p><p><strong>Design: </strong>This was a prospective, cross-sectional study.</p><p><strong>Methods: </strong>Lens densitometric (LD) analysis and specular microscopy were performed before, after, and 1 month after ALRP treatment, by an expert ophthalmologist, blinded to the medical status of the patients. LD analysis was performed using a Pentacam HR (Oculus, Wetzlar, Germany) and a Specular Microscope CEM-530 (Nidek, Japan) was used for endothelial cell analysis.</p><p><strong>Results: </strong>The evaluation was made on 81 eyes of 41 patients, with a mean age of 54.46 ± 6.7 years. LD, after ALRP, was significantly more than before ALRP (<i>p</i> < 0.001). There was no statistically significant difference in LD, before ALRP, and 1 month after ALRP (<i>p</i> = 0.262). There was a statistically significant increase in LD after ALRP compared to before ALRP, but it decreased after 1 month. There was an increase in the coefficient of variance (CV) after ALRP compared to before ALRP but it was not statistically significant (<i>p</i> = 0.188). There was no statistically significant difference in CV between before ALRP and 1 month after ALRP (<i>p</i> = 1.000). There was no statistically significant difference in the cell density, the hexagonality percentage between before ALRP, after ALRP, and 1 month after ALRP (<i>p</i> = 0.993, and 0.863, respectively).</p><p><strong>Conclusion: </strong>ALRP may affect the lens densitometry temporarily during the procedure. Thermal damage may be the reason for increased lens densitometry.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/4f/10.1177_25158414231189071.PMC10395167.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信